Amgen Will Not Pursue Sensipar Indication In Chronic Renal Insufficiency Patients
This article was originally published in The Pink Sheet Daily
Phase III study of secondary hyperparathyroidism drug in patients with chronic renal insufficiency demonstrated incidences of hypocalcemia.
You may also be interested in...
Amgen's chronic kidney disease treatment Sensipar includes precautions on hypocalcemia
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.